Agenda
-
Coffee and registration
-
Keynote
- Session 1: Current practice for Reach substance evaluation
-
ECHA overview of REACH substance evaluation
-
Industry case study: How to address a listing of your substance proactively
-
MS perspective: Process, case studies and strategies
Christian Unkelbach
Scientific Officer, Federal Institute for Occupational Health and Safety, Germany -
Refreshments and networking
-
Achievements, challenges and recommendations from an NGO perspective
- Survey of achievements under evaluation
- Bottle-necks in the substance evaluation process
- Member states’ lack of regulatory follow-up after substance evaluation
-
Q&A and panel discussion:
Based on experiences with a substance by substance approach what is working well and what could be further improved?
Christian Unkelbach
Scientific Officer, Federal Institute for Occupational Health and Safety, Germany -
Lunch
- Session 2: Current Reach substance evaluation decisions and conclusions
-
Moderator
-
Regulatory follow-up to substance evaluation decisions and conclusions
- Introduction
- SEv decisions follow-up: how it works in FR / FR statistics / positive and negative points from FR experience / proposals for improvement
- SEv conclusions follow-up: how it works in FR / FR statistics / positive and negative points from FR experience / proposals for improvement
- Conclusion
-
The enforcement of substance evaluation decisions/conclusions
-
ECHA’s Board of Appeal decisions on substance evaluations
- The Board of Appeal’s main decisions on substance evaluation;
- Recent General Court judgments on the Board of Appeal’s powers of review
-
Challenging substance evaluation decisions before ECHA's Board of Appeal
-
Refreshments and networking
-
Q&A and panel discussion: The evolution of substance evaluation
- How lessons learned from substance evaluations can inform future work
- The role of ECHA’s Board of Appeal in substance evaluation
- Interactions between the evaluating member states, ECHA and registants during the final stage of the evaluation
- Session 3: Work in progress towards optimizing the process - assessment in groups of substances
-
Moderator
-
Industry experience with first combined compliance check - a pilot case that could define the model for the future of ECHA’s combined evaluation
- The first time compliance check (CCH) and Substance Evaluation (SEv) take place in parallel
- The first time both processes take place on a group of metals
- The first time the SEv decisions were circulated to all registrants
-
Substance evaluation on groups of substances
- How to address concerns for multiple substances by requesting further information on only a sub-set of substances in a group or a category
Petra van Kesteren
Senior advisor REACH, Netherlands National Institute for Public Health and the Environment, The Netherlands -
Concerns about animal testing for substance evaluations
- Animal testing principles under REACH
- Mechanisms in REACH for avoiding testing on animals
- Substance evaluation compared to dossier evaluation
- Concerns about substance evaluation and testing on animals
- Improvements following appeals
- Scope for further improvements to substance evaluation
- The future of REACH, obligations for testing only as a last resort and the promotion of alternative methods
-
Q&A and panel discussion:
- What do we need to generate information on a group of substances?
- What are the implications for animal testing?
- How can we make the grouping approach work between all the stakeholders? (communication, costs, etc)
-
End of conference
